PROK vs. ALEC, VALN, ALLO, HUMA, VYGR, CCCC, EDIT, TSHA, ADPT, and ITOS
Should you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Alector (ALEC), Valneva (VALN), Allogene Therapeutics (ALLO), Humacyte (HUMA), Voyager Therapeutics (VYGR), C4 Therapeutics (CCCC), Editas Medicine (EDIT), Taysha Gene Therapies (TSHA), Adaptive Biotechnologies (ADPT), and iTeos Therapeutics (ITOS). These companies are all part of the "biological products, except diagnostic" industry.
Alector (NASDAQ:ALEC) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.
ProKidney has lower revenue, but higher earnings than Alector. ProKidney is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alector had 1 more articles in the media than ProKidney. MarketBeat recorded 2 mentions for Alector and 1 mentions for ProKidney. ProKidney's average media sentiment score of 1.34 beat Alector's score of 0.46 indicating that Alector is being referred to more favorably in the media.
Alector currently has a consensus price target of $14.86, indicating a potential upside of 186.26%. ProKidney has a consensus price target of $9.50, indicating a potential upside of 292.56%. Given Alector's higher probable upside, analysts clearly believe ProKidney is more favorable than Alector.
Alector has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
85.8% of Alector shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 14.0% of Alector shares are held by company insiders. Comparatively, 45.0% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Alector received 138 more outperform votes than ProKidney when rated by MarketBeat users. However, 66.67% of users gave ProKidney an outperform vote while only 60.25% of users gave Alector an outperform vote.
ProKidney has a net margin of 0.00% compared to ProKidney's net margin of -134.34%. Alector's return on equity of 0.00% beat ProKidney's return on equity.
Summary
Alector beats ProKidney on 9 of the 17 factors compared between the two stocks.
Get ProKidney News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProKidney Competitors List
Related Companies and Tools
